McCullough A R, Steidle C P, Kaufman J, Goldfischer E R, Klee B, Carlsson M
Sexual Health Fertility and Microsurgery, New York University School of Medicine, New York, NY 10016, USA.
Int J Impot Res. 2008 Jul-Aug;20(4):388-95. doi: 10.1038/ijir.2008.21. Epub 2008 Jun 5.
In two randomized, double-blind, placebo-controlled trials of 100 mg sildenafil citrate, men (N=601) with mild to moderate erectile dysfunction (ED) attempted intercourse 8 h (range, 7-9 h) postdose. The baseline to end-of-treatment improvement in the sildenafil groups vs placebo was greater (P<0.001) for the per-patient proportion (PPP) of 'yes' responses to the Sexual Encounter Profile question 3 (SEP3: successful intercourse (primary outcome)) (odds ratio (OR)=3.2 (trial 1), 7.6 (trial 2) and 5.6 (pooled data)); PPP of erection hardness score 4 (EHS 4, completely hard and fully rigid) (OR=6.2 (trial 1) and 10.9 (trial 2)); scores on the International Index of Erectile Function; and other EHS and SEP outcomes. Two to three times as many men were satisfied with sildenafil vs placebo treatment (Erectile Dysfunction Inventory of Treatment Satisfaction Index >50). Thus, responsiveness to 100 mg sildenafil may persist for 8 h postdose in men with mild to moderate ED.
在两项针对100毫克枸橼酸西地那非的随机、双盲、安慰剂对照试验中，患有轻度至中度勃起功能障碍（ED）的男性（N = 601）在服药后8小时（范围为7 - 9小时）尝试性交。西地那非组与安慰剂组相比，从基线到治疗结束时，对于性接触概况问题3（SEP3：性交成功（主要结局））的“是”回答的患者比例（PPP）有更大改善（P < 0.001）（优势比（OR）= 3.2（试验1），7.6（试验2）和5.6（汇总数据））；勃起硬度评分4（EHS 4，完全坚硬且完全勃起）的PPP（OR = 6.2（试验1）和10.9（试验2））；国际勃起功能指数评分；以及其他EHS和SEP结局。对西地那非治疗满意的男性人数是对安慰剂治疗满意人数的两到三倍（治疗满意度指数勃起功能障碍量表> 50）。因此，对于轻度至中度ED的男性，服用100毫克西地那非后的反应可能在服药后8小时持续存在。
